School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, Sichuan Province, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China.
J Integr Med. 2021 May;19(3):191-202. doi: 10.1016/j.joim.2021.01.008. Epub 2021 Jan 14.
Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease involving exocrine glands. Current studies have found that the occurrence of the disease is closely related to genetic, environmental and neuroendocrine factors, as well as abnormal activation of T and B lymphocytes. The etiology and pathogenesis of pSS is complex, and there is a lack of specific targeted drugs. Traditional Chinese medicines (TCMs) have been comprehensively investigated for their treatment effects on pSS. Through a systematic review of the literature, we summarized the TCMs used to treat pSS, and find that there are four major ways that TCMs are used, including upregulation of aquaporin proteins, suppression of cell apoptosis, suppression of the abnormal activation of B lymphocytes and suppression of the abnormal activation of T lymphocytes (balancing T helper type [Th]1/Th2 & Th17/Treg and suppressing follicular helper T [Tfh] cells). However, there are not enough data about the active constituents, quality control, pharmacokinetics, toxicity and modern preparations of these TCMs; therefore, more investigations are needed. This paper highlights the importance of TCMs for treating pSS and provides guidance for future investigations.
原发性干燥综合征(pSS)是一种涉及外分泌腺的慢性自身免疫性疾病。目前的研究发现,该病的发生与遗传、环境和神经内分泌因素以及 T 和 B 淋巴细胞的异常激活密切相关。pSS 的病因和发病机制复杂,缺乏特异性靶向药物。中药(TCM)已被广泛研究用于治疗 pSS。通过对文献的系统回顾,我们总结了用于治疗 pSS 的 TCM,发现 TCM 有四大作用方式,包括上调水通道蛋白、抑制细胞凋亡、抑制 B 淋巴细胞的异常激活和抑制 T 淋巴细胞的异常激活(平衡辅助性 T 细胞 1/辅助性 T 细胞 2 和 Th17/Treg 并抑制滤泡辅助性 T [Tfh]细胞)。然而,关于这些 TCM 的活性成分、质量控制、药代动力学、毒性和现代制剂的研究数据还不够充分;因此,需要进行更多的研究。本文强调了 TCM 治疗 pSS 的重要性,并为未来的研究提供了指导。
Stem Cell Res Ther. 2022-6-3
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2022-9-26
Health Technol Assess. 2001
Evid Based Complement Alternat Med. 2022-8-12